The market has yet to recognize Vertex's accelerating cash flow and growing future prospects.
News & Analysis: Vertex Pharmaceuticals
Despite working together on a major project, these two biotech stocks couldn't be more different from a growth perspective.
These biotech stocks are great picks -- but for very different reasons.
Success is in these three great healthcare stocks' DNA.
Which stock wins in a matchup between these two successful biotechs?
Great business models. Great growth prospects. Great moats. These three stocks check off all the boxes for buying and holding for years to come.
The pharma and biotech industries are high risk. But Vertex Pharmaceuticals is boldly soldiering on and wisely investing where it has a competitive advantage.
Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
The biotech just announced a potentially game-changing acquisition.
These healthcare winners have such strong competitive advantages that their theme song could be MC Hammer's "U Can't Touch This."
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.